TNFRSF8 and Hodgkins lymphoma: In the case of HL, improved response rates were associated with the treatment strategies of CD30/CD16A BSABs combined with pembrolizumab (ORR, 83%), ICI combination therapies (ORR, 74%), or ICI combination therapies accompanied with BV administration (ORR, 82%) in patients with R/R HL (Fig. 2a and Supplementary Table S1) [27, 49, 53, 56].